Published in Immunotherapy on April 01, 2013
Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy | NCT00991224
Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. J Infect Dis (2015) 1.04
Engineering broadly neutralizing antibodies for HIV prevention and therapy. Adv Drug Deliv Rev (2016) 0.86
Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS. Mol Ther Methods Clin Dev (2016) 0.85
HIV-specific CD8+ T cells and HIV eradication. J Clin Invest (2016) 0.85
Challenges and strategies for the eradication of the HIV reservoir. Curr Opin Immunol (2016) 0.84
Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. J Virol (2015) 0.84
HIV cure research: a formidable challenge. J Virus Erad (2015) 0.83
The clinical applications of genome editing in HIV. Blood (2016) 0.79
Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs. Front Immunol (2015) 0.77
Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection. Curr Opin HIV AIDS (2015) 0.77
Broadly neutralizing antibody and the HIV reservoir in acute HIV infection: a strategy toward HIV remission? Curr Opin HIV AIDS (2015) 0.77
Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions. Drugs (2015) 0.77
Cytomegalovirus-Infected Cells Resist T Cell Mediated Killing in an HLA-Recognition Independent Manner. Front Microbiol (2016) 0.75
Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells. Biomaterials (2016) 0.75
Novel immunological strategies for HIV-1 eradication. J Virus Erad (2015) 0.75
Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells. EBioMedicine (2017) 0.75
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med (1999) 7.77
The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity (1999) 6.80
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest (2008) 6.15
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood (2009) 4.98
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A (2007) 4.96
Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med (1995) 4.65
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med (2006) 4.42
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med (2008) 2.64
Nef-mediated downregulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes. J Virol (2002) 1.85
A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther (2002) 1.83
Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals. Proc Natl Acad Sci U S A (2007) 1.82
HIV controllers: how do they tame the virus? Trends Immunol (2007) 1.61
Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. J Virol (2011) 1.57
RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther (2009) 1.55
Safer CARS. Mol Ther (2010) 1.46
Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses. J Virol (2012) 1.29
From crucial to negligible: functional CD8⁺ T-cell responses and their dependence on CD4⁺ T-cell help. Eur J Immunol (2012) 1.27
Chemokine receptor 5 knockout strategies. Curr Opin HIV AIDS (2011) 1.22
Vaccine design for CD8 T lymphocyte responses. Cold Spring Harb Perspect Med (2011) 1.14
HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication. J Leukoc Biol (2000) 1.14
Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment. Mol Ther (2012) 1.10
Dual personality of memory T cells. Nature (1999) 1.06
Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy. Mol Ther (2009) 1.03
Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood (1997) 1.00
Increased levels of regulatory T cells (Tregs) in human immunodeficiency virus-infected patients after 5 years of highly active anti-retroviral therapy may be due to increased thymic production of naive Tregs. Clin Exp Immunol (2008) 0.98
HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. Blood (2011) 0.97
Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy (2010) 0.94
PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines. Mol Ther (2012) 0.93
Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization. J Acquir Immune Defic Syndr (2009) 0.91
Multiple roles of CD4 and CD8 in T cell activation. J Immunol (2010) 0.86
Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs. J Virol (2012) 0.83
Human immunodeficiency virus interactions with CD8+ T lymphocytes. Curr HIV Res (2008) 0.81
Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med (2012) 3.39
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood (2003) 1.55
Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes. J Immunol (2011) 1.00
Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients. Pediatr Hematol Oncol (2013) 0.86
De novo T-lymphocyte responses against baculovirus-derived recombinant influenzavirus hemagglutinin generated by a naive umbilical cord blood model of dendritic cell vaccination. Vaccine (2009) 0.85
Evaluation and management of BK virus-associated nephropathy following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 0.85
T-cell therapies for Epstein-Barr virus-associated lymphomas. Pediatr Hematol Oncol (2011) 0.76
Gene Therapy for Pediatric Cancer: State of the Art and Future Perspectives. J Biomed Biotechnol (2003) 0.75
Opportunities and challenges of proteomics in pediatric patients: circulating biomarkers after hematopoietic stem cell transplantation as a successful example. Proteomics Clin Appl (2014) 0.75
A Single Bout Of Exercise Enhances The Ex Vivo Manufacture Of Viral-specific T-cells: 330 Board #167 June 1, 9: 30 AM - 11: 00 AM. Med Sci Sports Exerc (2016) 0.75
Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas. Leuk Lymphoma (2010) 0.75
[Gene therapy of childhood cancers: current status and perspectives]. Bull Cancer (2003) 0.75